Articles tagged with Pancreatic Cancer
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Researchers used optical imaging to study the metabolic interactions between pancreatic cancer cells and surrounding non-cancer cells. They found that cancer cells can hijack the metabolic activity of these non-cancer cells to fuel tumor growth. This discovery could lead to new therapies targeting the tumor microenvironment.
A new review suggests that moderate coffee consumption can stimulate digestive processes and help movement through the colon. The study also found a possible association between coffee consumption and reduced risk of gallstones and certain liver diseases. However, further research is needed to confirm these findings.
Jonsson Comprehensive Cancer Center researchers have identified signaling mechanisms in pancreatic cancer cells that could be targeted for treatment. By inhibiting a specific protein, cancer cells' DNA can become damaged and induce programmed cell death, providing a potential new strategy for treating this aggressive form of cancer.
Researchers have identified a drug compound that makes pancreatic cancer cells more vulnerable to chemotherapy, reducing tumor size by about half and improving survival rates. The combination of ATI-450 with chemotherapy also mitigates side effects, including nausea and fatigue, in mice with human pancreatic cancer cells.
A study published in eLife reveals that a small signalling protein called ARL4C is overexpressed in pancreatic cancer patients, facilitating their aggressive behavior. By inhibiting ARL4C, researchers have shown promise in reducing the spread of pancreatic cancer cells, opening up new therapeutic avenues.
Researchers at Karolinska Institutet found that certain bacteria from the digestive system can cause damage to pancreatic cells, increasing the risk of malignant tumours. The study suggests that antibiotics could prevent this damage, offering a potential prophylactic intervention.
Researchers have identified two new symptoms – thirst and dark urine – associated with pancreatic cancer, which could help doctors diagnose the disease earlier. The study found 23 symptoms linked to pancreatic cancer, with patients often experiencing non-specific symptoms up to a year before diagnosis.
Researchers discovered that pancreatic injury leads to the formation of new cell types that can give rise to cancerous mutations. The study provides a valuable resource for understanding the processes behind pancreatic cancer and potential therapeutic targets.
A multi-center study demonstrated improved overall survival and quality of life for inoperable pancreatic cancer patients treated with MRIdian SMART, with a median survival of 26 months. The treatment showed low rates of major adverse events and was more effective than standard radiation therapy.
A new TGen study is exploring the use of checkpoint inhibitors to treat pancreatic cancer by modulating the tumor microenvironment and rendering it vulnerable to immunotherapies. The study, funded with a $1 million grant, aims to overcome the resistance of pancreatic cancer to treatments, including immune therapies.
The MUSC Hollings Cancer Center researchers are exploring the role of macroenvironment in pancreatic cancer-induced cachexia to address this debilitating condition. The team aims to provide new biological insight, which will be coordinated by four cores within the program project grant.
Researchers have developed a new approach to deliver therapeutic nucleic acids using nanoparticles coated with antibodies. This system targets cancer cells while sparing normal cells, showing improved efficacy and reduced toxicity compared to previous methods.
A study found that plasma cell-free miR-181c and tissue expression of miR-21, -210 accurately diagnose pancreatic adenocarcinoma (PA) with high accuracy. Further research is needed to validate its utility as a biomarker for PA diagnosis and monitoring.
Researchers used Caenorhabditis elegans to detect very-early-stage pancreatic cancer, achieving a reported sensitivity of 95.8%. The method showed promise for use in detecting patients with early PDAC, but the underlying mechanisms need further clarification.
A simulated screening process for a pancreatic cancer clinical trial showed that Black patients were significantly more likely than white patients to be excluded from trials. The study found that nutrition and infectious disease criteria disproportionately excluded Black patients, while a history of prior cancer treatment excluded more...
A research team at TUM has discovered that the protein TIMP1 is associated with a significantly higher risk of liver metastasis and death in male patients, particularly those with pancreatic, colon, and melanoma cancers. This finding may lead to improved diagnosis and targeted therapy options for men.
Researchers at Purdue University have successfully reversed pancreatic cancer progression in a new model called the acinus, which produces digestive enzymes. The study found that reactivating the PTF1a gene in cancerous cells converted them back into normal cells, revealing a potential path to treating pancreatic cancer.
Researchers have discovered a new approach to prime the tumor environment to make chemotherapy more effective for pancreatic ductal adenocarcinoma. By reducing stiffness and density of connective tissue, cancer spread was reduced by up to 50%. The study paves the way for a clinical trial to assess the therapy approach's effectiveness.
Researchers at Mount Sinai have developed a novel therapy called MS67 that effectively fights acute myeloid leukemia with mixed lineage leukemia rearrangement. The therapy degrades the WDR5 protein, which drives the proliferation of this type of leukemia and other cancers such as pancreatic cancer.
Researchers discovered a combination of two drugs can reduce inflammation following chemotherapy, preventing metastasis in pancreatic and liver cancer. The treatment targets the sEH and EP4 pathways, modulating inflammation to resolve cytokine storms.
Researchers found that antidepressants inhibit the growth of pancreatic and colon cancers in mice by blocking a mechanism used by cancer cells to evade the immune system. The findings suggest a promising approach for combining antidepressant drugs with immunotherapy to treat incurable cancers.
Researchers at Johns Hopkins Medicine have identified promising new targets for pancreatic cancer treatment and early detection, including glycosylated proteins that could be captured in the blood for diagnosis. The study also suggests new ways to improve immune response to these tumors.
Pancreatic cells display adaptive response to repeated inflammatory episodes, reprogramming gene expression and epigenetic regulation that cooperates with mutant KRAS to promote tumor formation. Inflammation drives long-term changes in epithelial cells that select for cancer-causing mutations.
Researchers at UNSW Sydney have found the specific protein responsible for keeping cells attached to collagen, a key finding for cancer research. The discovery could lead to new directions for cancer treatment by targeting the protein tropomyosin, which is involved in forming the anchor's chain.
Researchers at MIT developed a new way to grow pancreatic organoids using synthetic gel, allowing for study of interactions between tumors and environment. The gel can also be used to grow other types of tissue, including intestinal and endometrial tissue.
A population-based cohort study in Canada identified mortality patterns for different types of neuroendocrine tumors (NETs), revealing varying risks of cancer-related and non-cancer death. The study found that small NETs can be safely monitored, while larger tumors may require more aggressive treatment.
Black, Hispanic, Indigenous and Asian Americans remain underrepresented in pancreatic cancer clinical trials, despite federal mandates. The lack of diversity hurts patients and science alike, with racial and ethnic minorities accounting for a disproportionate burden of pancreatic cancer cases.
Researchers have discovered that inhibiting the GOT1 enzyme can promote ferroptosis, a type of programmed cell death, in pancreatic cancer cells by conserving nutrients and releasing iron stores. This study provides a new potential therapeutic target for treating pancreatic cancer.
Researchers discovered that hypoxia induces regional variations in gene-expression patterns in pancreatic cancer, with specific subpopulations of cancer cells surviving under hypoxic conditions. These findings suggest a link between hypoxia and aggressive tumor behavior, highlighting the need for targeted treatments.
Researchers have developed an immunotherapy strategy that combines three drugs to boost the immune system against tumors. The new therapy showed promising results in mice, with pancreatic tumors shrinking or disappearing completely in about half of the animals.
Researchers at Johns Hopkins Medicine have discovered that mebendazole, an anti-parasitic drug, can prevent and slow the growth of pancreatic cancer in genetically engineered mice. The study suggests that mebendazole may act similarly to collapsing cancer cells' structure and reducing inflammation.
Researchers at University of Pennsylvania School of Medicine developed a new technology for cellular immunotherapy that targets KRAS mutations in lung, colorectal, and pancreatic cancers. The therapy uses human cells to mobilize an immune system attack on mutated KRAS tumors and shrink them.
Scientists discovered that cells from different organs are differentially susceptible to activating mutations in cancer drivers, leading to distinct outcomes. The findings highlight the importance of understanding tissue-specific genetic networks and interactions to develop precise molecular interventions.
Researchers at Queen Mary University of London have discovered that immune cells can be stimulated to assemble into special structures within pancreatic cancer, improving the efficacy of chemotherapy. The findings suggest a potential therapeutic strategy for promoting an anti-tumour immune response in patients.
The MasSpec Pen technology has been shown to accurately identify healthy and cancerous tissue in pancreatic cancer surgeries, giving patients the greatest chance of survival. The device is over 100 times faster than current gold standard diagnostic methods.
The German National Academy of Sciences Leopoldina hosted a virtual symposium to discuss cancer research, particularly pancreatic cancer, and palliative care. Experts shared insights into the development of rare pancreatic tumors, mechanisms leading to metastasis formation, and resilience in palliative care.
Researchers found that reducing PTHrP levels can prevent metastasis and improve survival in mice with pancreatic cancer. The study also showed promising results with anti-PTHrP antibodies targeting human pancreatic cancer cells, offering a new potential treatment approach.
A new study has identified a protein called pentraxin 3 (PTX3) that may be used to aid in the diagnosis of pancreatic cancer. PTX3 levels were found to be significantly higher in patients with pancreatic ductal adenocarcinoma, a type of pancreatic cancer.
Researchers discovered that pancreatic cancer cells use a backup protein complex to survive when KRAS is blocked, allowing them to continue growing and dividing. This finding highlights the need for drugs that can target multiple molecules in cancer cells to improve treatment outcomes.
Researchers discovered a targeted drug, AT7519, effective in thwarting pancreatic tumors addicted to mutant KRAS gene. The study found that this CDK inhibitor selectively kills mutant KRAS-addicted cancer cells.
Researchers found that autophagy and the G2 checkpoint are interrelated processes in pancreatic cancer cells, helping them survive radiotherapy. Inhibiting the G2 checkpoint suppresses tumor growth, suggesting new tools to combat radiation-resistant PDAC cells.
A new study published in PLOS ONE demonstrates the potential of machine learning to identify high-risk patients with pancreatic cancer up to 2 years before diagnosis. The algorithm achieved high sensitivity and specificity rates, identifying 41% of patients under 60 as high risk and 72% of those diagnosed as having a detectable risk. T...
Chronic pancreatitis is a debilitating disease with poorly understood causative factors. Researchers at Osaka University identified disturbed molecular pathways and revealed underlying mechanisms that may inform effective therapy against the disease.
Researchers have developed a prognostic and therapeutic epigenetic biomarker for PDAC patients, predicting which are likely to benefit from traditional chemotherapy. The technology addresses a pressing clinical need by introducing the first ever epigenetic precision medicine approach to pancreatic cancer.
Researchers discovered a two-stage process leading to aggressive pancreatic cancer, where protein loss allows for tumor transformation and immune evasion. The study suggests reinstating the classical subtype could reduce metastasis.
Researchers find a way to target both pancreatic cancer cells and the scar tissue surrounding them, reducing tumor growth and spreading. A new clinical trial aims to test this approach with an existing anti-arthritis drug, potentially improving treatment response and patient survival.
A phase II study by Penn Medicine shows rucaparib helped control cancer growth in patients with BRCA or PALB2 genetic mutations. The results support the use of rucaparib as a maintenance therapy for pancreatic cancer patients, offering a safe and effective alternative to chemotherapy.
Researchers found that about half of pancreatic cancer cell lines are dependent on peroxiredoxin 4 for survival. Targeting PRDX4 led to DNA damage and cell death in cancer cells, but not normal cells. This discovery reveals a potential therapeutic window with less toxicity.
Researchers at Beth Israel Deaconess Medical Center have successfully created 3D organoid models of the human pancreas from human stem cells, including both acinar and ductal structures. The new platform could lead to the discovery of markers for early diagnosis and monitoring of pancreatic cancer.
Nagoya University researchers discovered a molecular pathway that enhances chemotherapy resistance in some pancreatic cancer patients. Targeting the taurine upregulating gene 1 (TUG1) RNA could improve patient response to therapy and increase overall survival.
A recent study published in Gastroenterology reveals that overexpression of the ZIP4 protein in patients with pancreatic cancer enables tumor cells to transform into a shape-shifting form, evading detection and metastasizing to other organs. Understanding this process is crucial for developing targeted therapies to stop metastasis.
Researchers found that CD40 agonist treatment before surgery improved T cell attack on tumors, with 82% of treated tumors being T-cell enriched. The treatment also reduced tumor-associated fibrosis and enhanced dendritic cells' maturity. Disease-free survival was 13.8 months, with median overall survival at 23.4 months.
Mutant KRAS and p53, the most frequently mutated genes in pancreatic cancer, work together through CREB1 to drive tumor growth and metastasis. Blocking CREB1 reversed these effects and reduced metastases, suggesting a promising new therapeutic target for this deadly cancer.
A new study from the University of Arizona Department of Surgery found that pancreatic cancer patients who undergo chemotherapy followed by resection live an average of 19.75 months, compared to 10.12 months for those who received only chemotherapy. The researchers suggest that surgery can improve survival even in difficult cases.
A UCLA team has been awarded two grants totaling $6 million to identify new ways to treat pancreatic cancer. The research aims to untangle the complexities of the disease and develop effective immunotherapeutic approaches.
Researchers discovered pancreatic cancer cells employ macropinocytosis, a novel pathway to procure nutrients when autophagy is inhibited, enabling them to thrive despite starvation. A combination of autophagy and macropinocytosis inhibitors resulted in rapid tumor regression in mouse models.
Researchers at Sanford Burnham Prebys found that blocking macropinocytosis in the thick tissue surrounding a pancreatic tumor slows tumor growth. The study suggests that macropinocytosis is an important driver of pancreatic cancer growth and provides a potential therapeutic target.
Researchers at the University of Texas MD Anderson Cancer Center discovered that collagen produced by cancer-associated fibroblasts slows tumor progression in pancreatic cancer. Collagen helps block immune signals that lead to suppression of anti-tumor immune response.
Researchers at Massachusetts General Hospital discovered that activating nuclear IL-33 in chronic inflammation promotes abnormal cell growth and division, leading to cancer. Inhibiting IL-33's expression may help prevent cancers associated with inflammation.
Researchers predict pancreatic cancer death rates will remain approximately stable for men but continue to rise in women. The researchers predict that 42,300 and 5,000 men in the EU and UK respectively will die from pancreatic cancer by the end of this year.